Deligönül, AdemAksoy, SeçilTezcan, GülçinTunca, BerrinKanat, ÖzkanÇubukcu, ErdemYılmazlar, TuncayÖztürk, ErsinEgeli, ÜnalÇeçener, GülşahAlemdar, AdemEvrensel, Türkkan2024-07-012024-07-012021-04-011945-0265https://doi.org/10.1089/gtmb.2020.0285https://www.liebertpub.com/doi/10.1089/gtmb.2020.0285https://hdl.handle.net/11452/42666Background and Aim: In 10-30% of colorectal cancer (CRC) patients, toxic reactions occur after fluoropyrimidine-based chemotherapy. A dihydropyridine dehydrogenase (DPYD) gene variant, c.1905 + 1G>A, leads to intolerance to fluoropyrimidines. Due to the low frequency of this variant in many populations, the prevalence of fluoropyrimidine-induced hematologic side effects in CRC patients with the c.1905 + 1G>A variant is unclear. In this study, we investigated the prevalence of the DPYD c.1905 + 1 variants in a Turkish CRC cohort and the potential effects of these variants on fluoropyrimidine-induced hematologic side effects.Materials and Methods: The DPYD c.1905 + 1 variant was genotyped using polymerase chain reaction-restriction fragment length polymorphism analysis and confirmed by Sanger sequencing in peripheral blood samples of 100 CRC patients who received fluoropyrimidine-based chemotherapy and 60 healthy volunteers. The association of c.1905 + 1 variants with susceptibility to hematologic side effects was evaluated.Results: The DPYD c.1905 + 1G>A variant was more common in the CRC group than in the healthy control group (p = 0.001). The presence of the c.1905 + 1G>A variant was associated with thrombocytopenia (p = 0.039) and anemia (p = 0.035). CRC patients with fluoropyrimidine-induced anemia had shorter disease-free survival than CRC patients without fluoropyrimidine-induced anemia (p = 0.0009).Conclusions: Before administering fluoropyrimidine-based chemotherapy, genetic screening for the DPYD c.1905 + 1G>A variant should be performed with the aim of preventing anemia and anemia-induced complications in CRC patients.eninfo:eu-repo/semantics/closedAccessDPYD c.1905+1G > AFluoropyrimidineAnemiaColorectal cancerBiochemistry & molecular biologyGenetics & heredityDPYD c.1905+1G>A promotes fluoropyrimidine-induced anemia, a prognostic factor in disease-free survival, in colorectal cancerArticle00064153860000427628325410.1089/gtmb.2020.0285